Sakar Healthcare Limited (SAKAR.NS)
INR 258.29
(6.94%)
INR 258.29
(6.94%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 116.7 Million INR | -8.53% |
| 2022 | 127.58 Million INR | -16.3% |
| 2021 | 152.42 Million INR | 42.69% |
| 2020 | 106.82 Million INR | 11.01% |
| 2019 | 96.22 Million INR | 37.25% |
| 2018 | 70.11 Million INR | 83.79% |
| 2017 | 38.14 Million INR | 12.92% |
| 2016 | 33.78 Million INR | 52.32% |
| 2015 | 22.17 Million INR | 20.77% |
| 2014 | 18.36 Million INR | 4.83% |
| 2013 | 17.51 Million INR | 21.23% |
| 2012 | 14.45 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 47.96 Million INR | 98.85% |
| 2024 Q1 | 24.12 Million INR | -22.71% |
| 2023 Q1 | 28.4 Million INR | -27.59% |
| 2023 Q2 | 36.35 Million INR | 28.0% |
| 2023 FY | 116.7 Million INR | -8.53% |
| 2023 Q4 | 31.2 Million INR | 50.45% |
| 2023 Q3 | 20.74 Million INR | -42.94% |
| 2022 Q2 | 19.44 Million INR | -32.43% |
| 2022 Q4 | 39.22 Million INR | -2.25% |
| 2022 FY | 127.58 Million INR | -16.3% |
| 2022 Q1 | 28.78 Million INR | -67.83% |
| 2022 Q3 | 40.12 Million INR | 106.32% |
| 2021 Q2 | 24.64 Million INR | -32.56% |
| 2021 Q1 | 36.54 Million INR | 110.51% |
| 2021 FY | 152.42 Million INR | 42.69% |
| 2021 Q4 | 89.48 Million INR | 7818.76% |
| 2021 Q3 | 1.13 Million INR | -95.41% |
| 2020 Q1 | 25.86 Million INR | -9.62% |
| 2020 FY | 106.82 Million INR | 11.01% |
| 2020 Q4 | 17.35 Million INR | -3.54% |
| 2020 Q3 | 17.99 Million INR | -60.55% |
| 2020 Q2 | 45.61 Million INR | 76.38% |
| 2019 Q3 | 22.09 Million INR | -24.82% |
| 2019 Q1 | 16.12 Million INR | -21.12% |
| 2019 FY | 96.22 Million INR | 37.25% |
| 2019 Q2 | 29.39 Million INR | 82.3% |
| 2019 Q4 | 28.61 Million INR | 29.51% |
| 2018 Q3 | 19.55 Million INR | -13.13% |
| 2018 Q4 | 20.43 Million INR | 4.54% |
| 2018 FY | 70.11 Million INR | 83.79% |
| 2018 Q1 | 8.31 Million INR | 0.0% |
| 2018 Q2 | 22.5 Million INR | 170.58% |
| 2017 FY | 38.14 Million INR | 12.92% |
| 2016 FY | 33.78 Million INR | 52.32% |
| 2016 Q4 | 23.32 Million INR | 0.0% |
| 2015 Q2 | 8.72 Million INR | 0.0% |
| 2015 Q3 | 2.91 Million INR | -66.62% |
| 2015 Q4 | 16.62 Million INR | 470.55% |
| 2015 FY | 22.17 Million INR | 20.77% |
| 2015 Q1 | 8.72 Million INR | 130.41% |
| 2014 FY | 18.36 Million INR | 4.83% |
| 2014 Q4 | 3.78 Million INR | 0.0% |
| 2013 FY | 17.51 Million INR | 21.23% |
| 2012 FY | 14.45 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 98.105% |
| Hester Biosciences Limited | 188.89 Million INR | 38.213% |
| Aarti Drugs Limited | 1.71 Billion INR | 93.192% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 94.619% |
| Albert David Limited | 754.2 Million INR | 84.525% |
| Alembic Limited | 2.68 Billion INR | 95.655% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.35% |
| Bafna Pharmaceuticals Limited | 73.47 Million INR | -58.833% |
| Bajaj HealthCare Limited | -837.93 Million INR | 113.928% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -1545.643% |
| Brooks Laboratories Limited | -195.91 Million INR | 159.57% |
| Eris Lifesciences Limited | 3.91 Billion INR | 97.023% |
| FDC Limited | 3.05 Billion INR | 96.176% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 97.522% |
| Gufic Biosciences Limited | 861.35 Million INR | 86.451% |
| Hikal Limited | 696 Million INR | 83.231% |
| Ind-Swift Limited | 142.31 Million INR | 17.991% |
| Innova Captab Limited | 943.45 Million INR | 87.63% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 91.318% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 48.044% |
| Jubilant Pharmova Limited | 771 Million INR | 84.863% |
| Lincoln Pharmaceuticals Limited | 933.04 Million INR | 87.492% |
| Lupin Limited | 19.14 Billion INR | 99.39% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 228.652% |
| Medico Remedies Limited | 82.9 Million INR | -40.768% |
| Morepen Laboratories Limited | 961.59 Million INR | 87.863% |
| Nectar Lifesciences Limited | 49.95 Million INR | -133.652% |
| Orchid Pharma Limited | 921.66 Million INR | 87.337% |
| Procter & Gamble Health Limited | 2 Billion INR | 94.193% |
| RPG Life Sciences Limited | 876.6 Million INR | 86.686% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 20.07% |
| Sigachi Industries Limited | 571.8 Million INR | 79.589% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 102.057% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 96.113% |
| Themis Medicare Limited | 435.23 Million INR | 73.185% |
| Unichem Laboratories Limited | -704.74 Million INR | 116.561% |
| Vaishali Pharma Limited | 7.18 Million INR | -1523.439% |
| Wanbury Limited | 559.56 Million INR | 79.143% |
| Windlas Biotech Limited | 581.87 Million INR | 79.942% |
| ZIM Laboratories Limited | 172.46 Million INR | 32.328% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 97.228% |
| Ipca Laboratories Limited | 5.47 Billion INR | 97.868% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.878% |
| Venus Remedies Limited | 284.9 Million INR | 59.036% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.632% |
| Divi's Laboratories Limited | 16 Billion INR | 99.271% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 92.774% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.39% |
| Sequent Scientific Limited | -358.69 Million INR | 132.538% |
| Laurus Labs Limited | 1.6 Billion INR | 92.731% |
| Neuland Laboratories Limited | 3 Billion INR | 96.111% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 97.888% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 100.777% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.698% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 74.049% |
| Wockhardt Limited | -4.63 Billion INR | 102.521% |
| Bal Pharma Limited | 73.92 Million INR | -57.881% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.79% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 84.532% |
| Par Drugs and Chemicals Limited | 145.01 Million INR | 19.517% |
| Caplin Point Laboratories Limited | 4.57 Billion INR | 97.447% |
| Shilpa Medicare Limited | 318.74 Million INR | 63.384% |
| Valiant Laboratories Limited | 3.19 Million INR | -3551.721% |
| Ajanta Pharma Limited | 8.16 Billion INR | 98.57% |
| Aarey Drugs & Pharmaceuticals Limited | 46.83 Million INR | -149.183% |
| Granules India Limited | 4.05 Billion INR | 97.121% |
| Medicamen Biotech Limited | 109.31 Million INR | -6.769% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 53.896% |
| Piramal Enterprises Limited | -16.83 Billion INR | 100.693% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 99.295% |
| NATCO Pharma Limited | 13.88 Billion INR | 99.159% |
| Suven Life Sciences Limited | -1.05 Billion INR | 111.107% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 159.158% |
| Strides Pharma Science Limited | -706.14 Million INR | 116.528% |
| Indoco Remedies Limited | 984.6 Million INR | 88.147% |
| Alpa Laboratories Limited | 167.76 Million INR | 30.433% |
| Lasa Supergenerics Limited | -217.3 Million INR | 153.707% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 103.014% |